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Abstract
Introduction: Previous studies have found higher circulating levels of tissue inhibitor of matrix metalloproteinase
(TIMP)-1 in nonsurviving septic patients than in surviving septic patients, and an association between the 372 T/C
genetic polymorphism of TIMP-1 and the risk of developing certain diseases. However, the relationship between
genetic polymorphisms of TIMP-1, circulating TIMP-1 levels and survival in patients with severe sepsis has not been
examined, and this was the objective of the study.
Methods: This multicentre, prospective, observational study was carried out in six Spanish ICUs. We determined
the 372 T/C genetic polymorphism of TIMP-1 (rs4898), serum levels of TIMP-1, matrix metalloproteinase (MMP)-9,
MMP-10, TNFa, IL-10 and plasma plasminogen activator inhibitor-1 (PAI-1). Survival at 30 days from ICU admission
was the endpoint assessed. The association between continuous variables was carried out using Spearman’s rank
correlation coefficient or Spearman’s rho coefficient. Multivariate logistic regression analysis was applied to
determine the association between the 372 T/C genetic polymorphism and survival 30 days from ICU admission.
Results: Of 275 patients with severe sepsis, 80 had genotype CC, 55 had genotype CT and 140 had genotype TT of the
372 T/C genetic polymorphism of TIMP-1. Patients with the T allele showed higher serum levels of TIMP-1 than patients
without the T allele (P = 0.004). Multiple logistic regression analysis showed that the T allele was associated with higher
mortality at 30 days (odds ratio = 2.08; 95% confidence interval = 1.06 to 4.09; P = 0.03). Survival analysis showed that
patients with the T allele presented lower 30-day survival than patients without the T allele (c2 = 5.77; P = 0.016). We
found an association between TIMP-1 levels and levels of MMP-9 (r = -0.19; P = 0.002), MMP-10 (r = 0.55; P <0.001),
TNFa (r = 0.56; P <0.001), IL-10 (r = 0.48; P <0.001) and PAI-1 (r = 0.49; P <0.001).
Conclusion: The novel findings of our study are that septic patients with the T allele in the 372 T/C genetic
polymorphism of TIMP-1 showed higher serum TIMP-1 levels and lower survival rate. The determination of the 372
T/C genetic polymorphism of TIMP-1 thus has prognostic implications and could help in the selection of patients
who may benefit from modulation of the MMP/TIMP balance.
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Introduction
Sepsis represents a systemic response of the immune sys-
tem to infection that leads to high mortality and costs
[1,2]. The pathophysiologic mechanisms of sepsis are not
well known and a better understanding of these processes
may allow unmasking of other mortality risk factors.
Matrix metalloproteinases (MMPs) are a family of zinc-
containing endoproteinases implicated in the degradation
and remodelling of the extracellular matrix. The regula-
tion of MMP activity is carried out by tissue inhibitors of
matrix metalloproteinases (TIMPs). MMPs have a role in
normal physiological functions such as the menstrual
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cycle, morphogenesis, tissue remodelling and angiogen-
esis, and in diseases with abnormal extracellular matrix
turnover, such as arthritis, tumour invasion, aneurysm
formation and atherosclerosis [3]. The role of MMPs/
TIMPs in sepsis remains unclear; however, the results of
some studies indicate that MMPs facilitate the recruit-
ment of leukocytes from the bloodstream to the site of
infection for eradication of the pathogen by proteolysis of
the basement membrane [4], and modulate inflammatory
[4] and prothrombotic responses [5,6].
Higher circulating levels of TIMP-1 have been reported
in nonsurviving septic patients than in surviving septic
patients [7-9]. An association between some genetic poly-
morphisms of the X-linked TIMP-1 gene and the risk of
developing certain diseases has been reported [10-23], the
372 T/C polymorphism being the variant most studied
[10-16]. However, the relationship between genetic poly-
morphism of TIMP-1, circulating TIMP-1 levels and sur-
vival in patients with severe sepsis has not been examined.
The objective of this study was thus to determine
whether there is an association between the 372 T/C
genetic polymorphism of TIMP-1, serum levels of TIMP-
1 and survival in patients with severe sepsis.
Materials and methods
Design and subjects
A multicentre, prospective, observational study was carried
out in six Spanish ICUs. The study was approved by the
Institutional Review Boards of the six hospitals: Hospital
Universitario de Canarias (La Laguna, Santa Cruz de
Tenerife, Spain), Hospital Universitario Nuestra Señora de
Candelaria (Santa Cruz de Tenerife, Spain), Hospital Uni-
versitario Dr. Negrín (Las Palmas de Gran Canaria, Spain),
Hospital Clínico Universitario de Valencia (Valencia,
Spain), Hospital San Jorge (Huesca, Spain) and Hospital
Insular (Las Palmas de Gran Canaria, Spain). Written
informed consent was obtained from the patients or from
the family members. All patients were Caucasian and suf-
fered from severe sepsis. The diagnosis of severe sepsis
was established according to the International Sepsis Defi-
nitions Conference [24].
Exclusion criteria were: age <18 years, pregnancy, lacta-
tion, HIV, white blood cell count <103/mm3, solid or hae-
matological tumours, or immunosuppressive, steroid or
radiation therapy.
Variables recorded
The following variables were recorded for each patient:
sex, age, diabetes mellitus, site of infection, microorgan-
ism responsible, bloodstream infection, adequate empiric
antimicrobial treatment, pressure of arterial oxygen/frac-
tion of inspired oxygen, creatinine, bilirubin, leukocyte
count, lactic acid, platelet count, International Normal-
ised Ratio (INR), activated partial thromboplastin time
(aPTT) and Acute Physiology and Chronic Health Evalua-
tion (APACHE) II score [25]. Measurements of circulating
levels of TIMP-1, MMP-9, MMP-10, TNFa, IL-10 and
plasminogen activator inhibitor-1 (PAI-1), as well as the
genetic determination of the TIMP-1 372 T/C polymorph-
ism were carried out in peripheral blood. Survival at
30 days from ICU admission was the endpoint assessed.
Determination of the 372 T/C genetic polymorphism of
TIMP-1 (rs4898)
Genotyping was performed by PCR and restriction frag-
ment length polymorphism analysis. DNA was prepared
from 3 ml peripheral blood using proteinase K treatment,
phenol-chloroform extraction and ethanol precipitation.
About 100 ng DNA were used as the template in PCR
using the primers 5’-GCACATCACTACCTGCAGTCT-3’
and 5’-GAAACAAGCCCACGATTTAG-3’, flanking the
372 T/C polymorphism (rs4898) of the TIMP-1 gene, and
the temperature profile 94°C-55°C-72°C for 30 seconds
each for 30 cycles. (C denotes a mutation introduced in
the primer in order to generate a BssSI restriction site
(CACGAG) in the C allele, while the T allele remains
uncut.) The amplified DNA was restricted with endonu-
clease BssSI (New England Biolabs, Boston, MA, USA) for
2 hours at 37°C. The resulting DNA fragments were sepa-
rated by gel electrophoresis in 2.5% agarose gel and visua-
lised under ultraviolet light. In the absence of a BssSI site,
a fragment of 175 base pairs was detected (T allele),
whereas fragments of 153 and 22 base pairs corresponded
to the C allele. Genotyping was performed in a blinded
manner.
Determination of serum TIMP-1, MMP-9, MMP-10, TNFa,
IL-10 and plasma PAI-1 levels
Blood samples were collected at ICU admission. Serum
separator tubes were used to determine TIMP-1 concen-
tration in serum; venous blood samples were taken and
centrifuged within 30 minutes at 1,000×g for 15 minutes,
and the serum was removed and frozen at -80°C until
measurement.
TIMP-1, MMP-9 and MMP-10 assays were performed
at the Atherosclerosis Research Laboratory of CIMA -
University of Navarra (Pamplona, Spain). A specific ELISA
(Quantikine®; R&D Systems, Abingdon, UK) was used in
accordance with the manufacturer’s instructions with a
serum dilution of 1:100, 1:80 and 1:2, respectively. The
interassay coefficient of variation was <8% (n = 20) and
the detection limits for the assays were 0.15 ng/ml, 0.31
ng/ml and 78.1 pg/ml, respectively.
TNFa, IL-10 and PAI-1 assays were performed at the
Laboratory Department of the Hospital Universitario de
Canarias (La Laguna, Santa Cruz de Tenerife, Spain).
TNFa and IL-10 determinations were performed by
solid-phase chemiluminescent immunometric assays
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(Immulite®; Siemens Healthcare Diagnostics Products,
Llanberis, UK). The interassay coefficients of variation
were <6.5% (n = 20) and <9.9% (n = 40), respectively, and
detection limits for the assays were 1.7 pg/ml and 1 pg/ml,
respectively. PAI-1 antigen was assayed by specific ELISA
(Imubind Plasma PAI-1 Elisa™; American Diagnostica,
Inc., Stanford, CT, USA). This assay detects latent (inac-
tive) and active forms of PAI-1 and PAI-1 complexes. The
interassay coefficient of variation was <5% (n = 20) and
the detection limit for the assay was 1 ng/ml.
Statistical methods
This series of patients was a nonprobabilistic sample and
the recruitment period was 18 months. This study
included 192 patients from a previous publication [8].
Continuous variables are reported as medians and inter-
quartile ranges. Categorical variables are reported as fre-
quencies and percentages. Comparisons of continuous
variables between groups were carried out using the Wil-
coxon-Mann-Whitney test. Comparisons between groups
on categorical variables were carried out with the chi-
square test. The association between continuous variables
was carried out using Spearman’s rank correlation coeffi-
cient or Spearman’s rho coefficient.
Thirty-day survival curves, using the T allele or non-T
allele of the 372 T/C genetic polymorphism of TIMP-1,
were represented using the Kaplan-Meier method and
compared by log-rank test. Multivariate logistic regression
analysis was applied to data from the whole sample and
separately by sex in order to determine the independent
contribution of the 372 T/C genetic polymorphism of
TIMP-1, lactic acid levels, APACHE II score and sex to
the prediction of mortality during the 30-day period. We
analysed, both globally and separately by sex, the relation-
ship between TIMP-1 levels and 30-day survival, control-
ling for lactic acid level and APACHE score.
Odds ratios (ORs) and 95% confidence intervals (CIs)
were calculated as measures of the clinical impact of the
predictor variables. Using linear regression modelling, we
analysed the relationship between the 372 T/C genetic
polymorphism of TIMP-1 and the infection site as inde-
pendent variables and TIMP-1 levels as the dependent
variable. P <0.05 was considered statistically significant.
Statistical analyses were performed with SPSS 17.0 (SPSS
Inc., Chicago, IL, USA) and NCSS 2000 (Jerry Hintze,
Kaysville, UT, USA).
Results
As shown in Table 1, a total of 275 patients with severe
sepsis were included, 80 with genotype CC (or male hemi-
zygous C), 55 with genotype CT and 140 with genotype
TT (or male hemizygous T) of the 372 T/C genetic poly-
morphism of TIMP-1 (rs4898). The calculated frequencies
for the C (0.393) and T (0.607) alleles in our sample were
similar to those obtained in the Exome Sequencing Project
cohort population (0.467 and 0.533, respectively) [26].
Since TIMP-1 is located on the × chromosome, men and
women were considered separately to test for Hardy-
Weinberg equilibrium among our genotypes. Using chi-
square tests to compare expected and observed genotypes,
we found no significant deviation from Hardy-Weinberg
predictions. There were no significant differences between
different genotypes in age, diabetes mellitus, site of infec-
tion, microorganism responsible, bloodstream infection,
adequate empiric antimicrobial treatment, pressure of
arterial oxygen/fraction of inspired oxygen, bilirubin, leu-
kocyte count, INR, aPTT and APACHE II score. However,
patients with the T allele showed higher serum creatinine
and lactic acid levels, and lower platelet count and male
sex. Besides, patients with the T allele of the 372 T/C
genetic polymorphism of TIMP-1 showed higher serum
levels of TIMP-1 (P = 0.004) and lower survival rate (P =
0.02) than patients without the T allele.
Thirty-day survival according to the different 372 T/C
genetic polymorphism of TIMP-1 was analysed separately
by sex. In men, we found higher survival in patients with
the C allele than in those with the T allele (53/70 (75.7%)
vs. 67/111 (60.4%); P = 0.04). In women, we did not find
significant differences in survival between patients with
C/C, C/T and T/T expression (8/10 (80%), 34/55 (61.8%)
vs. 17/29 (58.6%); P = 0.47).
As shown in Table 2, we found higher TIMP-1 levels in
nonsurvivors than in survivors globally; separately by sex
and 372 T/C genetic polymorphism of TIMP-1, we found
higher TIMP-1 levels in women and men with the T
allele (Table 2).
We found an association between TIMP-1 levels and
MMP-9 (r = -0.19; P = 0.002), MMP-10 (r = 0.55;
P <0.001), TNFa (r = 0.56; P <0.001), IL-10 (r = 0.48;
P <0.001) and PAI-1 (r = 0.49; P <0.001) levels, INR (r =
-0.42; P <0.001), aPTT (r = 0.29; P <0.001) and platelet
count (r = -0.18; P = 0.002).
As shown in Table 3, multiple logistic regression analy-
sis showed that the T allele of the 372 T/C genetic poly-
morphism of TIMP-1 was associated with higher mortality
at 30 days (OR = 2.08; 95% CI = 1.06 to 4.09; P = 0.03).
Separately by sex, we found a relationship between the T
allele of the 372 T/C genetic polymorphism of TIMP-1
and survival in men, after controlling for lactic acid level
and APACHE II score (OR = 1.44; 95% CI = 1.002 to
2.072; P = 0.049), but not in women (OR = 1.45; 95% CI =
0.57 to 3.64; P = 0.43).
As shown in Table 3, multiple logistic regression analy-
sis showed that TIMP-1 levels were associated with higher
mortality at 30 days after controlling for lactic acid level
and APACHE II score (OR = 1.001; 95% CI = 1.0002 to
Lorente et al. Critical Care 2013, 17:R94
http://ccforum.com/content/17/3/R94
Page 3 of 8
Table 1 Patient characteristics according to the 372 C/T genetic polymorphism of tissue inhibitor of matrix
metalloproteinase-1
Characteristic Without T allele (n = 80) With T allele (n = 195) P value
Gender (male) 70 (87.5) 111 (56.9) <0.001
Age (years) 62 (53 to 72) 60 (48 to 69) 0.12
Diabetes mellitus 26 (32.5) 60 (30.8) 0.77
Myocardial infarction 7 (8.8) 11 (5.6) 0.42
Chronic obstructive pulmonary disease 12 (15.0) 26 (13.3) 0.70
Asthma 2 (2.5) 4 (2.1) 0.99
Site of infection 0.86
Respiratory 47 (58.8) 106 (54.4)
Abdominal 23 (28.8) 57 (29.2)
Neurological 1 (1.3) 4 (2.1)
Urinary 2 (2.5) 12 (6.2)
Skin 3 (3.8) 8 (4.1)
Endocarditis 4 (5.0) 7 (3.6)
Others 0 (0) 1 (0.5)
Bloodstream infection 11 (13.8) 31 (15.9) 0.71
PaO2/FIO2 ratio 150 (103 to 248) 176 (107 to 262) 0.82
Creatinine (mg/dl) 1.00 (0.85 to 2.03) 1.40 (0.80 to 2.40) 0.02
Bilirubin (mg/dl) 0.80 (0.43 to 1.45) 0.90 (0.46 to 1.80) 0.64
Leukocytes (×103/mm3) 14.6 (10.2 to 20.0) 15.0 (9.1 to 20.4) 0.99
Lactic acid (mmol/l) 1.80 (1.20 to 3.10) 2.30 (1.30 to 4.60) 0.02
Platelets (×103/mm3) 227 (132 to 303) 165 (93 to 234) 0.007
INR 1.32 (1.06 to 1.55) 1.35 (1.14 to 1.58) 0.46
aPTT (seconds) 33 (29 to 44) 32 (28 to 41) 0.28
APACHE II score 19 (15 to 24) 20 (16 to 24) 0.41
TIMP-1 (ng/ml) 523 (355 to 707) 639 (444 to 880) 0.004
MMP-9 (ng/ml) 759 (389 to 1,224) 606 (275 to 1,022) 0.11
MMP-10 (pg/ml) 1706 (1,016 to 2,539) 1,795 (1,237 to 3,514) 0.12
TNFa (pg/ml) 27.8 (18.1 to 47.1) 31.8 (20.1 to 57.9) 0.37
IL-10 (pg/ml) 10.1 (5.6 to 55.4) 14.55 (6.0 to 60.5) 0.36
PAI-1 (ng/ml) 39.9 (25.2 to 63.4) 44.8 (24.6 to 71.5) 0.48
Survivors at 30 days 61 (76.3) 118 (60.5) 0.02
Data presented as number (percentage) or median (25th to 75th percentile). APACHE, Acute Physiology and Chronic Health Evaluation; aPTT, activated partial
thromboplastin time; INR, International Normalised Ratio; MMP, matrix metalloproteinase; PaO2/FIO2, pressure of arterial oxygen/fraction inspired oxygen; PAI-1,
plasminogen activator inhibitor-1; TIMP, tissue inhibitor of matrix metalloproteinase.
Table 2 TIMP-1 levels in surviving and nonsurviving patients according to sex and 372 T/C genetic polymorphism
Survival Nonsurvival P value
All patients 529 (355 to 706) 805 (510 to 1,027) <0.001
Women
C/C 436 (345 to 775) 662 (500 to 824) 0.43
C/T 583 (415 to 819) 862 (506 to 1,055) 0.03
T/T 465 (284 to 754) 742 (413 to 1,177) 0.046
Men
C allele 500 (333 to 657) 696 (370 to 936) 0.11
T allele 557 (437 to 715) 814 (616 to 1,055) <0.001
Data (ng/ml) presented as median (25th to 75th percentile). TIMP, tissue inhibitor of matrix metalloproteinase. {AU Query: Confirm table caption, contents and
footnote after editing to style}
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1.002; P = 0.008). Separately by sex, we found a relation-
ship between TIMP-1 levels and survival in women, after
controlling for lactic acid level and APACHE II score (OR
= 1.001; 95% CI = 1.0002 to 1.003; P = 0.048), but not in
men (OR = 1.0001; 95% CI = 0.999 to 1.001; P = 0.48).
Linear regression analysis showed that TIMP-1 levels
were associated with the 372 T/C genetic polymorphism
of TIMP-1 (regression coefficient = 114.4; 95% CI =
31.71 to 197.14; P = 0.007), but not with site of infection
(regression coefficient = 105.7; 95% CI = -45.12 to
256.48; P = 0.17).
Survival analysis showed that patients with the T allele
of the 372 T/C genetic polymorphism of TIMP-1 pre-
sented lower 30-day survival than those without the T
allele (c2 = 5.77; P = 0.016) (Figure 1).
Discussion
The novel findings of our study were that there is an
association between the 372 T/C genetic polymorphism
of TIMP-1 (rs4898), circulating levels of TIMP-1 and
30-day survival in patients with severe sepsis. Patients
with the T allele in the 372 T/C genetic polymorphism
of TIMP-1 showed higher serum TIMP-1 levels and
lower survival rate.
Although the exact mechanism by which this synon-
ymous SNP might affect function is unknown, the 372
T/C genetic polymorphism of TIMP-1 has been asso-
ciated with increased risk of developing certain diseases
[10-16]. However, an association between the 372 T/C
genetic polymorphism of TIMP-1 and survival in
patients with severe sepsis has not been previously
reported. The results of the different studies are contro-
versial; some found that the C allele was associated with
higher risk of certain diseases [10-13] while others
showed that the T allele was associated with higher risk
[14-16]. In the present study, septic patients with the T
allele had a lower rate of survival at 30 days.
A previous study showed that humans carrying the T
allele in the 372 T/C genetic polymorphism of TIMP-1
had increased susceptibility to Crohn’s disease and pre-
sented lower levels of TIMP-1 in surgically resected
macroscopically inflamed tissue [15]. In our study, how-
ever, we found that septic patients with this T allele had
a lower survival rate and showed higher serum levels of
TIMP-1. This is consistent with reports of higher circu-
lating levels of TIMP-1 in nonsurviving septic patients
than in surviving septic patients [7-9].
Table 3 Multiple logistic regression analysis to predict 30-day mortality.
Odds ratio 95% confidence interval P value
First model including all patients
Lactic acid 1.19 1.07 to 1.32 0.001
APACHE II 1.08 1.04 to 1.13 <0.001
Gender female 1.26 0.68 to 2.33 0.46
Presence of T allelea 2.08 1.06 to 4.09 0.03
Second model including only women
Lactic acid 1.18 1.02 to 1.36 0.03
APACHE II 1.10 1.02 to 1.18 0.009
Presence of T allelea 1.45 0.57 to 3.64 0.43
Third model including only men
Lactic acid 1.21 1.04 to 1.40 0.01
APACHE II 1.08 1.02 to 1.13 0.008
Presence of T allelea 1.44 1.002 to 2.072 0.049
Four model including all patients
Lactic acid 1.13 1.02 to 1.27 0.03
APACHE II 1.08 1.03 to 1.13 <0.001
TIMP-1 levels 1.001 1.0002 to 1.002 0.008
Five model including only women
Lactic acid 1.13 0.95 to 1.34 0.16
APACHE II 1.14 1.04 to 1.24 0.003
TIMP-1 levels 1.001 1.0002 to 1.003 0.048
Six model including only men
Lactic acid 1.13 1.06 to 1.62 0.01
APACHE II 1.10 1.02 to 1.19 0.02
TIMP-1 levels 1.0001 0.999 to 1.001 0.48
APACHE, Acute Physiology and Chronic Health Evaluation; TIMP, tissue inhibitor of matrix metalloproteinase. aT allele of the 372 T/C genetic polymorphism of TIMP-1.
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There is a relationship between coagulation and inflam-
mation response in sepsis [27-29] and it is possible that
MMPs/TIMPs play a role in that response. In our series,
septic patients carrying the T allele showed significantly
higher serum TIMP-1 levels and lower survival rate. The
reason for this is not clear; TIMP-1 forms noncovalent
bimolecular complexes with the active and latent forms of
MMP-9, and reduces MMP-9 activity [3,4]. Some studies
have reported that MMP-9 inhibits platelet aggregation
[30,31], that there is a positive correlation between TIMP-
1 and PAI-1 [32,33] and that there is a positive correlation
between TIMP-1 and plasma homocysteine [32]. We
found, for the first time in septic patients, a positive asso-
ciation between TIMP-1 levels and PAI-1 levels and
aPTT, and a negative association between TIMP-1 levels
and the INR and platelet count - these data suggest that
these patients had a higher anti-fibrinolytic state and acti-
vation of coagulation. We found that septic patients carry-
ing the T allele in the 372 T/C genetic polymorphism of
TIMP-1 had higher TIMP-1 levels than those without it.
We therefore believe that septic patients carrying the T
allele in the 372 T/C genetic polymorphism of TIMP-1
could have a prothrombotic/antifibrinolytic profile,
responsible for capillary thrombosis, multiple organ dys-
function and, finally, early death.
The 372 T/C genetic polymorphism of TIMP-1 is
located on the × chromosome, which means that men
have the C or T allele, and women have C/C, C/T or T/T.
This aspect is important since there are differences in the
findings according to patient gender. On the one hand,
globally, we found that patients without the T allele
showed better 30-day survival than those with the T allele.
Figure 1 Thirty-day survival according the T allele in the 372 C/T genetic polymorphism of TIMP-1. Kaplan-Meier curves showing the
cumulative proportion of survival patients at 30 days according to the presence or not of the T allele in the 372 C/T genetic polymorphism of
tissue inhibitor of matrix metalloproteinase (TIMP)-1.
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Separately by sex, men without the T allele had better 30-
day survival than those with the T allele but no differences
in survival were found between women patients with C/C,
C/T and T/T alleles. On the other hand, globally, we
found that nonsurvivors showed higher TIMP-1 levels
than survivors. Stratified by sex, nonsurviving women with
C/T and T/T and nonsurviving men with the T allele had
higher TIMP-1 levels than survivors; however, we did not
find differences in TIMP-1 levels between survivors and
nonsurvivors in women with C/C or men with the C allele.
Taken together, our results indicate an association
between the T allele and TIMP-1 levels, and that higher
TIPM-1 levels increased early mortality.
A noteworthy finding of the present study was that
TIMP-1 levels in both surviving and nonsurviving
patients were lower than those described in other series
[7,9]; however, the levels were significantly higher in
nonsurvivors than in survivors in all studies.
From a therapeutic perspective, modulators of MMP/
TIMP activity have been used successfully in septic ani-
mal models, reducing TIMP-1 and improving the prog-
nosis [34,35]. Determination of the 372 T/C genetic
polymorphism of TIMP-1 could thus help in the selec-
tion of patients who may benefit from modulation of
MMP/TIMP activity.
The present study has certain limitations. First, the sam-
ple size was relatively small; nevertheless, our nonprobabil-
istic sample was large enough to be able to show an
association between the 372 T/C genetic polymorphism of
TIMP-1 and 30-day survival. Second, it could be interest-
ing to determine other SNPs of TIMP-1; however, we
tested rs4898 because this SNP has previously been asso-
ciated with other diseases [10-16]. rs4898 is a synonymous
coding SNP, but it is in strong linkage disequilibrium with
other TIMP-1 polymorphisms, as documented in the Hap-
Map database for European Community populations [26].
The rs4898 SNP can thus be used as a tag SNP for the
region of interest. It is possible that this rs4898 SNP is
linked to other SNPs associated with the same effect, as
was previously proposed in a study by Skarmoutsou and
colleagues to explain the association between this poly-
morphism and systemic sclerosis [16]. Third, we did not
determine the rs4898 SNP in healthy control subjects;
however, the objective of our study was not to determine
the association between the occurrence of sepsis and the
polymorphism, but rather the association between sepsis
survival and the polymorphism.
Conclusion
The novel findings of our study are that septic patients
with the T allele in the 372 T/C genetic polymorphism of
TIMP-1 showed higher serum TIMP-1 levels and lower
survival rate. Determination of the 372 T/C genetic poly-
morphism of TIMP-1 thus has prognostic implications
and could help in the selection of patients who may bene-
fit from modulation of the MMP/TIMP balance.
Key messages
• Septic patients with T allele in the 372 T/C genetic
polymorphism of TIMP-1 showed higher serum
TIMP-1 levels and lower survival rate
• The determination of the 372 T/C genetic poly-
morphism of TIMP-1 has prognostic implications and
could help in the selection of patients who may benefit
from modulation of the MMP/TIMP balance.
Abbreviations
APACHE: Acute Physiology and Chronic Health Evaluation; aPTT: activated
partial thromboplastin time; INR: International Normalised Ratio; CI:
confidence interval; ELISA: enzyme-linked immunosorbent assay; MMP:
matrix metalloproteinase; OR: odds ratio; PAI-1: plasminogen activator
inhibitor-1; PCR: polymerase chain reaction; SNP: single nucleotide
polymorphism; TIMP: tissue inhibitor of matrix metalloproteinase; TNF:
tumour necrosis factor.
Authors’ contributions
LLo conceived, designed and coordinated the study, participated in
acquisition of data, and drafted the manuscript. MM, JS-V, JB, LLa and CD
participated in acquisition of data. AJ interpreted the data. FP and ES carried
out the molecular genetic studies. JMB-L, JAP, JO and JAR carried out the
immunoassays. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
This study was supported, in part, by the grants FIS/PI-10-1572, I3SNS-INT-11-
063 and I3SNS-INT-12-087 from Instituto de Salud Carlos III (Madrid, Spain)
and by UTE Project CIMA (University of Navarra).
Author details
1Intensive Care Unit, Hospital Universitario de Canarias, Ofra s/n La Laguna
38320, Santa Cruz de Tenerife, Spain. 2Intensive Care Unit, Hospital
Universitario Nuestra Señora Candelaria, Carretera Rosario s/n, Santa Cruz
Tenerife 38010, Spain. 3Research Unit, Hospital Universitario de Canarias, La
Laguna 38320, Santa Cruz de Tenerife, Spain. 4Intensive Care Unit, Hospital
Universitario Dr. Negrín, Barranco de la Ballena s/n, Las Palmas de Gran
Canaria 35010, Spain. 5Intensive Care Unit, Hospital Clínico Universitario de
Valencia, Avenida Blasco Ibáñez nº17, Valencia 46004, Spain. 6Intensive Care
Unit, Hospital San Jorge de Huesca, Avenida Martínez de Velasco nº36,
Huesca 22004, Spain. 7Intensive Care Unit, Hospital Insular, Plaza Dr. Pasteur
s/n, Las Palmas de Gran Canaria 35016, Spain. 8Laboratory Deparment,
Hospital Universitario de Canarias, Ofra s/n, La Laguna 38320, Santa Cruz de
Tenerife, Spain. 9Atherosclerosis Research Laboratory, CIMA-University of
Navarra, Avenida Pío XII nº55, Pamplona 31008, Spain.
Received: 30 January 2013 Revised: 4 April 2013
Accepted: 25 May 2013 Published: 25 May 2013
References
1. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R,
Carlet J, Le Gall JR, Payen D, Sepsis Occurrence in Acutely Ill Patients
Investigators: Sepsis in European intensive care units: results of the SOAP
study. Crit Care Med 2006, 34:344-353.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR:
Epidemiology of severe sepsis in the United States: analysis of
incidence, outcome, and associated costs of care. Crit Care Med 2001,
29:1303-1310.
3. Brinckerhoff CE, Matrisian LM: Matrix metalloproteinases: a tail of a frog
that became a prince. Nat Rev Mol Cell Biol 2002, 3:207-214.
Lorente et al. Critical Care 2013, 17:R94
http://ccforum.com/content/17/3/R94
Page 7 of 8
4. Elkington PT, O’Kane CM, Friedland JS: The paradox of matrix
metalloproteinases in infectious disease. Clin Exp Immunol 2005,
142:12-20.
5. Lijnen H: Matrix metalloproteinases and cellular fibrinolytic activity.
Biochemistry (Mosc) 2002, 67:92-98.
6. Santos-Martínez MJ, Medina C, Jurasz P, Radomski MW: Role of
metalloproteinases in platelet function. Thromb Res 2008, 121:535-542.
7. Hoffmann U, Bertsch T, Dvortsak E, Liebetrau C, Lang S, Liebe V, Huhle G,
Borggrefe M, Brueckmann M: Matrix-metalloproteinases and their
inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in
severe sepsis. Scand J Infect 2006, 38:867-872.
8. Lorente L, Martín MM, Labarta L, Díaz C, Solé-Violán J, Blanquer J, Orbe J,
Rodríguez JA, Jiménez A, Borreguero-León JM, Belmonte F, Medina JC,
Llimiñana MC, Ferrer-Agüero JM, Ferreres J, Mora ML, Lubillo S, Sánchez M,
Barrios Y, Sierra A, Páramo JA: Matrix metalloproteinase-9, -10, and tissue
inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of
severity and mortality in sepsis. Crit Care 2009, 13:R158.
9. Lauhio A, Hästbacka J, Pettilä V, Tervahartiala T, Karlsson S, Varpula T,
Varpula M, Ruokonen E, Sorsa T, Kolho E: Serum MMP-8, -9 and TIMP-1 in
sepsis: high serum levels of MMP-8 and TIMP-1 are associated with fatal
outcome in a multicentre, prospective cohort study. Hypothetical impact
of tetracyclines. Pharmacol Res 2011, 64:590-594.
10. Hung KH, Hung HW, Yang HB, Lu CC, Wu JJ, Sheu BS: Host single
nucleotide polymorphisms of MMP-9 -1562/TIMP-1 372 have gender
differences in the risk of gastric intestinal metaplasia after Helicobacter
pylori infection. Helicobacter 2009, 14:580-587.
11. Yi YC, Chen MK, Chen LY, Ho ES, Ying TH, Wang PH, Yang SF: Genetic
polymorphism of the tissue inhibitor of metalloproteinase-1 is
associated with an increased risk of endometrial cancer. Clin Chim Acta
2009, 409:127-131.
12. Wei JC, Lee HS, Chen WC, Shiu LJ, Yang SF, Wong RH: Genetic
polymorphisms of the matrix metalloproteinase-3 (MMP-3) and tissue
inhibitors of matrix metalloproteinases-1 (TIMP-1) modulate the
development of ankylosing spondylitis. Ann Rheum Dis 2009,
68:1781-1786.
13. Meijer MJ, Mieremet-Ooms MA, Sier CF, van Hogezand RA, Lamers CB,
Hommes DW, Verspaget HW: Matrix metalloproteinases and their tissue
inhibitors as prognostic indicators for diagnostic and surgical recurrence
in Crohn’s disease. Inflamm Bowel Dis 2009, 15:84-92.
14. Indelicato M, Chiarenza V, Libra M, Malaponte G, Bevelacqua V, Marchini M,
McCubrey JA, Stivala F, Scorza R, Mazzarino MC: Analysis of TIMP-1 gene
polymorphisms in Italian sclerodermic patients. J Clin Lab Anal 2006,
20:173-176.
15. Meijer MJ, Mieremet-Ooms MA, van Hogezand RA, Lamers CB,
Hommes DW, Verspaget HW: Role of matrix metalloproteinase, tissue
inhibitor of metalloproteinase and tumor necrosis factor-alpha single
nucleotide gene polymorphisms in inflammatory bowel disease. World J
Gastroenterol 2007, 13:2960-2966.
16. Skarmoutsou E, D’Amico F, Marchini M, Malaponte G, Scorza R,
Mazzarino MC: Association of TIMP-1 +372 SNP with digital ulcer
manifestation in female systemic sclerosis patients. Hum Immunol 2012,
73:950-953.
17. van Diemen CC, Postma DS, Siedlinski M, Blokstra A, Smit HA, Boezen HM:
Genetic variation in TIMP1 but not MMPs predict excess FEV1 decline in
two general population-based cohorts. Respir Res 2011, 12:57.
18. Ogata T, Shibamura H, Tromp G, Sinha M, Goddard KA, Sakalihasan N,
Limet R, MacKean GL, Arthur C, Sueda T, Land S, Kuivaniemi H: Genetic
analysis of polymorphisms in biologically relevant candidate genes in
patients with abdominal aortic aneurysms. J Vasc Surg 2005,
41:1036-1042.
19. Lose F, Thompson PJ, Duffy D, Stewart GA, Kedda MA: A novel tissue
inhibitor of metalloproteinase-1 (TIMP-1) polymorphism associated with
asthma in australian women. Thorax 2005, 60:623-628.
20. Kumar M, Bhadoria DP, Dutta K, Singh S, Gupta J, Kumar R, Chhillar AK,
Yadav V, Singh B, Sharma GL: Combinatorial effect of TIMP-1 and α1AT
gene polymorphisms on development of chronic obstructive pulmonary
disease. Clin Biochem 2011, 44:1067-1073.
21. Xiao B, Tian W, Zhao DH, Wu CA, Wang N, Zhang YZ: Relationship
between 666C > T polymorphism of TIMP-1 and lumbar intervertebral
disc degeneration. Zhonghua Yi Xue Za Zhi 2010, 90:2939-2942.
22. Burkhardt J, Petit-Teixeira E, Teixeira VH, Kirsten H, Garnier S, Ruehle S,
Oeser C, Wolfram G, Scholz M, Migliorini P, Balsa A, Westhovens R,
Barrera P, Alves H, Pascual-Salcedo D, Bombardieri S, Dequeker J,
Radstake TR, Van Riel P, van de Putte L, Bardin T, Prum B, Buchegger-
Podbielski U, Emmrich F, Melchers I, Cornelis F, Ahnert P: Association of
the X-chromosomal genes TIMP1 and IL9R with rheumatoid arthritis.
J Rheumatol 2009, 36:2149-2157.
23. Valdes AM, Hassett G, Hart DJ, Spector TD: Radiographic progression of
lumbar spine disc degeneration is influenced by variation at
inflammatory genes: a candidate SNP association study in the Chingford
cohort. Spine (Phila Pa 1976) 2005, 30:2445-2451.
24. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J,
Opal SM, Vincent JL, Ramsay G, International Sepsis Definitions Conference:
2001 SCCM/ ESICM/ ACCP/ATS/SIS International Sepsis Definitions
Conference. Intensive Care Med 2003, 29:530-538.
25. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of
disease classification system. Crit Care Med 1985, 13:818-829.
26. Single Nucleotide Polymorphism Database. [http://www.ncbi.nlm.nih.gov/
projects/SNP/snp_ref.cgi?rs = 4898].
27. Kinasewitz GT, Yan SB, Basson B, Comp P, Russell JA, Cariou A, Um SL,
Utterback B, Laterre PF, Dhainaut JF, PROWESS Sepsis Study Group:
Universal changes in biomarkers of coagulation and inflammation occur
in patients with severe sepsis, regardless of causative micro-organism
[ISRCTN74215569]. Crit Care 2004, 8:R82-R90.
28. Esmon CT: Interactions between the innate immune and blood
coagulation systems. Trends Immunol 2004, 25:536-542.
29. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS: Pulmonary coagulopathy as a
new target in therapeutic studies of acute lung injury or pneumonia -a
review. Crit Care Med 2006, 34:871-877.
30. Sheu JR, Fong TH, Liu CM, Shen MY, Chen TL, Chang Y, Lu MS, Hsiao G:
Expression of matrix metalloproteinase-9 in human platelets: regulation
of platelet activation in in vitro and in vivo studies. Br J Pharmacol 2004,
143:193-201.
31. Lee YM, Lee JJ, Shen MY, Hsiao G, Sheu JR: Inhibitory mechanisms of
activated matrix metalloproteinase-9 on platelet activation. Eur J
Pharmacol 2006, 537:52-58.
32. Aznaouridis K, Vlachopoulos C, Dima I, Vasiliadou C, Ioakeimidis N, Baou K,
Stefanadi E, Stefanadis C: Divergent associations of tissue inhibitors of
metalloproteinases-1 and -2 with the prothrombotic/fibrinolytic state.
Atherosclerosis 2007, 195:212-215.
33. Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT,
Pinsky DJ, Marmur JD: Tissue inhibitor of metalloproteinase-1 (TIMP-1) is
an independent predictor of all-cause mortality, cardiac mortality, and
myocardial infarction. Am Heart J 2006, 151:1101, e1-e8.
34. Zhu S, Ashok M, Li J, Li W, Yang H, Wang P, Tracey KJ, Sama AE, Wang H:
Spermine protects mice against lethal sepsis partly by attenuating
surrogate inflammatory markers. Mol Med 2009, 15:275-282.
35. Ho CH, Hsu SP, Yang CC, Lee YH, Chien CT: Sialic acid reduces acute
endotoxemia-induced liver dysfunction in the rat. Shock 2009, 32:228-235.
doi:10.1186/cc12739
Cite this article as: Lorente et al.: The 372 T/C genetic polymorphism of
TIMP-1 is associated with serum levels of TIMP-1 and survival in
patients with severe sepsis. Critical Care 2013 17:R94.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lorente et al. Critical Care 2013, 17:R94
http://ccforum.com/content/17/3/R94
Page 8 of 8
